Merck & Co. (MRK) : United Bank Va scooped up 2,790 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 25, 2016. The investment management firm now holds a total of 64,957 shares of Merck & Co. which is valued at $3,806,480.Merck & Co. makes up approximately 3.59% of United Bank Va’s portfolio.
Other Hedge Funds, Including , Guinness Asset Management Ltd boosted its stake in MRK in the latest quarter, The investment management firm added 22,050 additional shares and now holds a total of 101,300 shares of Merck & Co. which is valued at $5,936,180. Merck & Co. makes up approx 1.62% of Guinness Asset Management Ltd’s portfolio.First National Bank Of Omaha reduced its stake in MRK by selling 631 shares or 1.22% in the most recent quarter. The Hedge Fund company now holds 51,053 shares of MRK which is valued at $3,001,406. Merck & Co. makes up approx 0.23% of First National Bank Of Omaha’s portfolio.Naples Global Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 1,125 additional shares and now holds a total of 30,201 shares of Merck & Co. which is valued at $1,798,470. Merck & Co. makes up approx 0.72% of Naples Global Advisors’s portfolio.Berson Corrado Investment Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 2 additional shares and now holds a total of 6,038 shares of Merck & Co. which is valued at $358,355. Merck & Co. makes up approx 0.13% of Berson Corrado Investment Advisors’s portfolio.
Merck & Co. opened for trading at $59.01 and hit $59.2 on the upside on Friday, eventually ending the session at $58.66, with a gain of 0.39% or 0.23 points. The heightened volatility saw the trading volume jump to 84,91,237 shares. Company has a market cap of $162,372 M.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.